IRWD

$3.25

Post-MarketAs of Mar 17, 8:00 PM UTC

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.25
Potential Downside
16.9%
Whystock Fair Value$2.70
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase typ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$529.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.67
Beta
Defensive asset. Lower volatility than the S&P 500.
0.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.08

Recent News

Zacks
Mar 12, 2026

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?

Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 6, 2026

Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?

Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 27, 2026

A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance

Q4 results and 2026 guidance in focus Ironwood Pharmaceuticals (IRWD) has drawn fresh attention after reporting its Q4 and full year 2025 results, alongside reiterating 2026 total revenue guidance of US$450 million to US$475 million. The latest report combined a Q4 sales decline and a small quarterly net loss with higher full year net income. This gives investors a mixed snapshot to weigh against the reiterated 2026 outlook. See our latest analysis for Ironwood Pharmaceuticals. The Q4 results...

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
GuruFocus.com
Feb 25, 2026

Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highlights: Strong LINZESS Sales and ...

Ironwood Pharmaceuticals Inc (IRWD) reports robust LINZESS sales growth and outlines strategic plans for increased revenue and debt reduction in 2026.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 25, 2026

Ironwood Pharmaceuticals Q4 Earnings Call Highlights

Ironwood Pharmaceuticals (NASDAQ:IRWD) executives highlighted stronger demand trends for LINZESS, a revamped pricing approach intended to improve 2026 net sales performance, and key next steps for the company’s apraglutide development program during the company’s fourth-quarter and full-year 2025 in

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.